Ascendis Pharma A/S Announces Third Quarter 2017 Financial Results Conference Call on November 16 COPENHAGEN, Denmark, Nov. 02, 2017 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq:ASND), a biopharmaceutical company that utilizes its innovative TransCon technology to address significant unmet...

Ascendis Pharma A/S Announces Pricing of Public Offering of ADSs COPENHAGEN, Denmark, Sept. 27, 2017 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq:ASND), a clinical stage biopharmaceutical company, today announced the pricing of its underwritten public offering...

Ascendis Pharma A/S Announces Dosing of Subjects in Phase 1 Trial of TransCon PTH COPENHAGEN, Denmark, Sept. 26, 2017 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq:ASND), a biopharmaceutical company that utilizes its innovative TransCon technology to address significant unmet...